Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KODAK-ICN RESEARCH VENTURE TO FOCUS ON DISCOVERY OF ANTIVIRAL, ANTI-AGING AGENTS

Executive Summary

KODAK-ICN RESEARCH VENTURE TO FOCUS ON DISCOVERY OF ANTIVIRAL, ANTI-AGING AGENTS, a recent press release announcing the formation of the joint research institute indicated. According to the release, the institute will "explore new biomedical compounds," dedicating "much of its research exclusively to preclinical studies of new antiviral and anti-aging substances." $45 mil. will be funneled into the formation and operation of the Nucleic Acid Research Institute by the two companies over a period of six years, the release said. When fully operational, the institute, which will be located at ICN's Costa Mesa, California facility, will employ more than 150 people. The institute will be headed by Waldon Jolley, Loma Linda University Medical Center, who will serve as president with additional responsibility for pharmacological research. Roland Robins, Brigham Young University Medical Center, will direct molecular research, and Robert Smith, UCLA, will supervise biomedical research. Commenting upon the importance of the research to Eastman Kodak, L. J. Thomas, senior VP and director of research for Kodak, said in the release: "We expect the Institute to build on ICN's pioneering work in the area of nucleic acid research, leading to specific substances with practical applications." The venture with ICN represents the latest step in Kodak's involvement in the health care field. Historically, the company has provided the industry with radiographic films and screens. Last February, Kodak established a biotechnology unit to expand its interests and capabilities in the biotechnology area ("The Pink Sheet" Feb. 25, T&G-1). ICN has one product in the pipeline, Virazole (ribavirin), with an NDA pending for the treatment of respiratory syncytial virus.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS008243

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel